VYNE Therapeutics Inc (NASDAQ: VYNE) has experienced a rise in its stock price by 7.14 compared to its previous closing price of 2.52. However, the company has seen a gain of 7.57% in its stock price over the last five trading days. globenewswire.com reported 2025-02-20 that BRIDGEWATER, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced that VYNE’s management will participate in two investor conferences in March.
Is It Worth Investing in VYNE Therapeutics Inc (NASDAQ: VYNE) Right Now?
Company’s 36-month beta value is 1.16.Analysts have differing opinions on the stock, with 3 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for VYNE is 12.24M, and currently, short sellers hold a 1.01% ratio of that floaft. The average trading volume of VYNE on February 21, 2025 was 104.84K shares.
VYNE’s Market Performance
VYNE’s stock has seen a 7.57% increase for the week, with a -2.53% drop in the past month and a 0.00% fall in the past quarter. The volatility ratio for the week is 8.14%, and the volatility levels for the past 30 days are at 8.69% for VYNE Therapeutics Inc The simple moving average for the past 20 days is 7.80% for VYNE’s stock, with a 13.79% simple moving average for the past 200 days.
Analysts’ Opinion of VYNE
Many brokerage firms have already submitted their reports for VYNE stocks, with BTIG Research repeating the rating for VYNE by listing it as a “Buy.” The predicted price for VYNE in the upcoming period, according to BTIG Research is $8 based on the research report published on November 18, 2024 of the previous year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see VYNE reach a price target of $7. The rating they have provided for VYNE stocks is “Buy” according to the report published on December 06th, 2021.
VYNE Trading at -2.45% from the 50-Day Moving Average
After a stumble in the market that brought VYNE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -37.21% of loss for the given period.
Volatility was left at 8.69%, however, over the last 30 days, the volatility rate increased by 8.14%, as shares sank -0.74% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +5.47% upper at present.
During the last 5 trading sessions, VYNE rose by +7.57%, which changed the moving average for the period of 200-days by +8.00% in comparison to the 20-day moving average, which settled at $2.50. In addition, VYNE Therapeutics Inc saw -19.40% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VYNE starting from LEPORE PATRICK G, who purchase 15,000 shares at the price of $2.92 back on Jan 15 ’25. After this action, LEPORE PATRICK G now owns 51,472 shares of VYNE Therapeutics Inc, valued at $43,800 using the latest closing price.
Stock Fundamentals for VYNE
Current profitability levels for the company are sitting at:
- -76.47 for the present operating margin
- 1.0 for the gross margin
The net margin for VYNE Therapeutics Inc stands at -68.93. The total capital return value is set at -0.59. Equity return is now at value -90.47, with -71.12 for asset returns.
Based on VYNE Therapeutics Inc (VYNE), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -244.8. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -143.34.
Currently, EBITDA for the company is -29.26 million with net debt to EBITDA at 0.44. When we switch over and look at the enterprise to sales, we see a ratio of 48.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.81.
Conclusion
In a nutshell, VYNE Therapeutics Inc (VYNE) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
